
Pharmaceutical Executive Daily: Egetis Sells Priority Review Voucher for $190 Million
5.11.2026
0:00
2:27
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat on improving how tumors are tested after recurrence.
Więcej odcinków z kanału "Pharmaceutical Executive"



Nie przegap odcinka z kanału “Pharmaceutical Executive”! Subskrybuj bezpłatnie w aplikacji GetPodcast.








